It proved that immune checkpoint inhibitors might have no difference (the OS of HR, 1.11; 95% CI, 0.80–1.55) compared with chemotherapy for NSCLC patients having EGFR mutation. Here, EGFR is linked to non-small cell lung carcinoma.